U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 07, 2019 at 09:02 pm
Share
U.S. Stem Cell, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 1.297 million compared to USD 1.820 million a year ago. Operating loss was USD 534,143 compared to USD 823,314 a year ago. Net loss was USD 839,126 compared to USD 1.244 million a year ago. For the half year, total revenue was USD 2.606 million compared to USD 3.533 million a year ago. Operating loss was USD 933,244 compared to USD 832,610 a year ago. Net loss was USD 1.512 million compared to USD 1.383 million a year ago.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
U.S. STEM CELL, INC. 
